Related references
Note: Only part of the references are listed.Germline JAK2 Mutation in a Family with Hereditary Thrombocytosis
Adam J. Mead et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study
Henrik Frederiksen et al.
BLOOD (2011)
PRISMA Statement
David Moher et al.
EPIDEMIOLOGY (2011)
Myeloproliferative Neoplasms: Molecular Pathophysiology, Essential Clinical Understanding, and Treatment Strategies
Ayalew Tefferi et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Hereditary thrombocytosis not as innocent as thought? Development into acute leukemia and myelofibrosis
Hidde L. A. Posthuma et al.
BLOOD (2010)
Hereditary myeloproliferative disorders
Radek C. Skoda
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Autoimmunity and the risk of myeloproliferative neoplasms
Sigurdur Y. Kristinsson et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria
Martha Wadleigh et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2010)
The 2008 World Health Organization Classification System for Myeloproliferative Neoplasms Order Out of Chaos
Ayalew Tefferi et al.
CANCER (2009)
Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24 577 first-degree relatives of 11 039 patients with myeloproliferative neoplasms in Sweden
Ola Landgren et al.
BLOOD (2008)
Familial chronic myeloproliferative disorders: the state of the art
Elisa Rumi
HEMATOLOGICAL ONCOLOGY (2008)
The JAK2V617F mutation is acquired secondary to the predisposing alteration in familial polycythaemia vera
H Cario et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
The World Health Organization (WHO) classification of the myeloid neoplasms
JW Vardiman et al.
BLOOD (2002)
Share Paper
